HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

BACKGROUND: The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at explorin...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Retrovirology
Main Authors: Ensoli, Fabrizio, Cafaro, Aurelio, Casabianca, Anna, Tripiciano, Antonella, Bellino, Stefania, Longo, Olimpia, Francavilla, Vittorio, Picconi, Orietta, Sgadari, Cecilia, Moretti, Sonia, Cossut, Maria R Pavone, Arancio, Angela, Orlandi, Chiara, Sernicola, Leonardo, Maggiorella, Maria T, Paniccia, Giovanni, Mussini, Cristina, Lazzarin, Adriano, Sighinolfi, Laura, Palamara, Guido, Gori, Andrea, Angarano, Gioacchino, Di Pietro, Massimo, Galli, Massimo, Mercurio, Vito S, Castelli, Francesco, Di Perri, Giovanni, Monini, Paolo, Magnani, Mauro, Garaci, Enrico, Ensoli, Barbara
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2015
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414440/
https://ncbi.nlm.nih.gov/pubmed/25924841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12977-015-0151-y
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים